Clinical trial · no report yet · Phase 3
PANKU-Lung03
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
- NCT06500026 ↗
- Active, not recruiting
- Sichuan Baili Pharmaceutical Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- BL-B01D1; Topotecan
- Arms
- BL-B01D1 · Experimental
- Topotecan · Experimental
- Enrollment
- 722
- Primary outcomes
- Overall survival (OS)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. with Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Start
- Aug 7, 2024
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06500026 · updated Apr 17, 2026
Publications
linked from the registry- Zhao Y, Zhao H, Wang Q, Yang K, Li Y, Fu Z, Yang W, He Z, Wang Y, Ma Y, Yang Y, Fang W, Xiao S, Zhu H, Zhu Y, Zhang L, Huang Y. Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. J Clin Oncol. 2026 Jul 24:JCO2600243. doi: 10.1200/JCO-26-00243. Online ahead of print. PubMed 42497381